Loading...
Loading...
AYLA| Name | Value |
|---|---|
| Revenues | 0.1M |
| Cost of Revenue | 0.1M |
| Gross Profit | 0.0M |
| Operating Expense | 10.1M |
| Operating I/L | -10.1M |
| Other Income/Expense | 0.0M |
| Interest Income | 0.0M |
| Pretax | -10.1M |
| Income Tax Expense | 0.1M |
| Net Income/Loss | -10.2M |
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company specializing in developing and commercializing small molecule therapeutics for rare and aggressive cancers. Their lead product candidate, AL101, is a potent, selective, injectable small molecule gamma secretase inhibitor (GSI) in Phase II clinical trial for recurrent/metastatic adenoid cystic carcinoma with Notch-activating mutations. Additionally, the company is developing AL102, an oral small molecule GSI in Phase II/III pivotal study for desmoid tumors, and has a collaboration with Novartis to develop AL102 for multiple myeloma treatment.
